Firesorb® Displayed in Taiwan Transcatheter Therapeutics 2017

Taibei, China – From January 7 to January 8, the in-house developed innovative product Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb®") of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was displayed in the annual meeting "Taiwan Transcatheter Therapeutics" ("TTT 2017") in Taibei, Taiwan. During the congress, Professor Chaowei Mu of Fuwai Hospital of Chinese Academy of Medical Sciences was invited by MicroPort® to release the six-month follow-up results of Firesorb® FUTURE-I Clinical Trial, which was well received by attendees.
The annual meeting TTT is the largest and the most influential academic meeting of interventional cardiology in Taiwan, which usually has many domestic and international cardiologists gathering together to share and discuss the updated technique and knowledge on interventional cardiovascular therapy, and meanwhile to watch live cases related to that field.
During this year's congress, Professor Chaowei Mu released the six-month clinical, angiographic, IVUS, and OCT results of Firesorb® FUTURE-I Clinical Trial. The clinical trial enrolled 45 patients and the primary endpoint is 30-day target lesion failure, including cardiac death, myocardial infarction of target vessel and TLR (Target lesion Revascularization) resulted from ischemia. The attendees spoke highly of Firesorb®'s safety, efficacy, and its unique design. As the second-generation fully bioresorbable scaffold, Firesorb® features thinner strut that lowers the crossing profile, shortens the bio-degradation time and reduces the risk of postoperative thrombosis. In Firesorb®'s target-eluting design, the drug only retains on one surface that contacts blood vessels, with 60% less drug loadings compared to similar products. Such design reduces the dose of drug, enhances the efficiency of the treatment, and prevents a large amount of drug residual from remaining in the body for a long time, while achieving the same clinical efficacy as other bioresorbable scaffolds.
In the TTT 2016, MicroPort® used to assist the team of Zhongshan Hospital of Fudan University to complete a live case of coronary interventional therapy performed by Academician Junbo Ge and Professor Juying Qian, which was highly recognized by experts in attendance. With the development of its international business, it is expected that in such similar congresses MicroPort® will provide attendees with different viewpoints and innovative technologies regarding interventional cardiovascular therapy, further promote the academic exchange between domestic and international cardiologists, and at the same time enhance the company's market expansion in Taiwan.